Format

Send to

Choose Destination
Crit Rev Oncol Hematol. 2016 Jun;102:65-72. doi: 10.1016/j.critrevonc.2016.03.020. Epub 2016 Apr 2.

Ten years of HPV vaccines: State of art and controversies.

Author information

1
Department of Obstetrics, Gynecology, Campus Bio Medico University of Rome, Via Álvaro del Portillo, 200, 00128, Rome, Italy.
2
Department of Obstetrics, Gynecology, Campus Bio Medico University of Rome, Via Álvaro del Portillo, 200, 00128, Rome, Italy. Electronic address: s.lopez@unicampus.it.
3
Department of Obstetrics, Gynecology, Campus Bio Medico University of Rome, Via Álvaro del Portillo, 200, 00128, Rome, Italy; Unit of Obstetrics and Gynecology, Magna Graecia University of Catanzaro, Italy.

Abstract

The human papillomavirus (HPV) represents one of the most common sexually transmitted infections and it has been related to cervical cancer. The HPV vaccines prevent infection with certain species of HPV associated with the development of cervical cancer or genital warts. We carried out a PubMed search up to 2015 evaluating all randomized studies published in literature. This review discusses the current status of HPVs vaccines on the global market, efficacy, safety profiles, controversies and future vaccine developments. Three HPVs vaccines are currently on the global market: bivalent, quadrivalent and ninevalent. Bivalent and quadrivalent vaccines can protect against almost 70% of cervical HPV-related cancerous and precancerous conditions and the ninevalent vaccine, instead, provides a protection against almost 90%. The use of vaccinations raised several controversies in the last years and, currently, is not possible to establish which type of vaccine is most effective, however all of them are safe.

KEYWORDS:

Bivalent; HPV; Ninevalent; Quadrivalent; Vaccine

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center